Applied BioMath, a company that offers model-informed drug discovery and development support, announced that they will participate in the Next-Generation Conjugates Summit in Boston, Massachusetts from February 21-23, 2023. Joshua Apgar, PhD, the company's Co-founder and CSO, will deliver a presentation titled "More than the Sum of Their Parts: Integrating data and knowledge of ADCs in a QSP platform model to predict efficacy and toxicity" on Wednesday, February 22nd at 2:00 p.m.
In the presentation, Dr. Apgar will discuss how quantitative systems pharmacology (QSP) modeling can help guide antibody drug conjugate (ADC) design and development to create a platform to guide design properties and understand the therapeutic window. Applied BioMath was awarded a grant in June 2020 by the National Institutes of Health for an ADC platform model to facilitate efficient knowledge discovery and enable rapid knowledge qualification in support of QSP models for ADC projects. The company hopes to provide a comprehensive model describing the mechanism of action for all known ADCs to navigate design complexities. To learn more about Applied BioMath, visit www.appliedbiomath.com.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!